Alpha @AlAlphaResearch

@HunterAllen4 😉👍

@HunterAllen4 Appreciate it! $OCC being slept on is exactly right. Profitable quarter, data center acceleration, and most people still haven’t connected the dots on what AI infrastructure buildout means for fiber optic demand. Glad someone else is watching this one. 🔥

@HunterAllen4 🙇‍♀️

When I wrote about $OPTT in April, it was 1 buoy in the water off San Diego. One DHS contract. One proof point. Today $OPTT announced it’s actively expanding defense engagement efforts in Europe. Let me show you what’s happened in between. Five concurrent PowerBuoy deployments in the U.S. now. Three for DHS, one for the U.S. Navy, one for a research institution. Three WAM-Vs and a PowerBuoy operating in the UAE. Active deployments in Greece and Taiwan. All three PowerBuoys simultaneously transmitting real time data from offshore at depths exceeding 1,000m, integrated directly into #Anduril ’s Lattice platform. Autonomous docking and charging demo completed. And today, formal European defense engagement expansion announced. Here’s the honest read on this. The market is still looking at $OPTT as a small loss making marine company. The financials are still rough, the pipeline is real but uncontracted revenue, and the stock is thinly traded. That’s not nothing and I’m not going to pretend the risks aren’t there. But the company itself has moved. Quietly and steadily, from one research buoy to a multi continent autonomous maritime network running live for DHS, Navy, UAE defense customers, and now actively pursuing European defense contracts. That’s not the same company the market is pricing. I keep thinking about $ONDS. When it was trading under $1, nobody was paying attention. The backlog was building, the defense relationships were forming, and the market still saw a small drone company losing money. Then the revenue hit, the contracts closed, and the re-rating came fast. The pattern isn’t identical but the dynamic is familiar. If $OPTT closes one or two European defense contracts, the conversation changes. NATO nations are actively increasing maritime security spending right now, and the technology they need, persistent autonomous offshore surveillance with no crew and no fuel, is exactly what @OceanPowerTech builds. That’s not a coincidence. That’s positioning. 🔗proactiveinvestors.com/companies/news…

Alpha @AlAlphaResearch

2 months ago

Yes, this is $OPTT. And what’s happening here is a lot more interesting than just a Coast Guard surveillance story. @OceanPowerTech Ocean Power Technologies just deployed its first PowerBuoy under a $6.5M DHS contract off the California coast last week. Each buoy sits offshore

1 1 14 5K 4

$OCC Optical Cable just reported Q2 FY2026 and the number that matters most is the one at the bottom. Net income positive ~$1.1M. The company just turned profitable. Revenue hit $22.2M, up 26.6% year over year. That’s not the same trajectory as Q1’s 4.4% growth. Something accelerated. The company said it plainly on the call. Enterprise, data center, and severe duty markets drove the increase. Gross margin expanded again to 34.2% from 32.7% last quarter and 29.4% a year ago. Manufacturing operating leverage is kicking in, meaning every incremental dollar of revenue is dropping more to the bottom line than before. The data center acceleration is the part worth understanding. On the Q1 call three months ago, management said they were seeing increased quotes and orders in the data center sector particularly in January and expected it to grow through the year. Q2 just proved that out. Revenue up 26.6% with data center explicitly called out as a driver. That’s not coincidence. That’s AI infrastructure buildout pulling fiber optic cable demand with it. Here’s the part most people miss about $OCC specifically. AI data centers aren’t just about GPUs. Every GPU cluster needs fiber optic cabling to connect servers within racks, racks within rows, rows within buildings, and buildings across campuses. The bandwidth demands at 400G and 800G per lane mean you can’t use copper beyond very short distances. You need fiber everywhere. $OCC makes exactly that, across enterprise, data center, military, industrial, and harsh environment applications. The Lightera strategic partnership is also worth watching. Lightera took a 7.24% stake in OCC and the collaboration is designed to expand product offerings and market reach. CEO said on the Q2 call they’re confident in OCC’s ability to capitalize on momentum in the second half of the year. Stock is still small cap and thinly traded. Cash position was tight at $126K at the end of Q1. The profitability in Q2 helps but this isn’t a fortress balance sheet. Still early. But a fiber optic cable manufacturer turning profitable for the first time in years, with data center explicitly driving the acceleration, right in the middle of the largest AI infrastructure buildout in history. That’s a setup that doesn’t come around often in a small cap.

SpaceX ( $SPCX )IPO is June 12. One week away. And right now there are six funds that already hold SpaceX pre IPO. But they’re very different trades depending on what you’re actually trying to own. $NASA (Tema Space Innovators ETF) is the most talked about. Launched March 30, 2026, crossed $2.48B in AUM in under three months. #SpaceX exposure through an SPV at roughly 6.5% of the portfolio, implying a SpaceX market cap of $1.51 trillion. Pure-play space economy, actively managed, 42 holdings including Rocket Lab $RKLB at 10.6%, AST SpaceMobile $ASTS at 6.6%, Planet Labs $PL at 6.5%, Intuitive Machines $LUNR at 6.2%, Firefly Aerospace $FLY at 5.1%. $XOVR (ERShares Private-Public Crossover ETF) has the highest SpaceX concentration at roughly 14.4%, implying a valuation around $1.55 trillion. VC Growth ETF, not a space ETF. SpaceX is the headline holding but the mandate covers other private and public category-defining companies. $DXYZ (Destiny Tech100) is a closed end fund holding a concentrated portfolio of private tech companies. SpaceX is one of the top positions alongside other pre IPO names like OpenAI and Anthropic. $RONB (Baron First Principles ETF) holds SpaceX direct shares alongside a diversified portfolio of growth companies. Less concentrated on space specifically but meaningful SpaceX exposure through actual shares rather than an SPV. $VCX (Fundrise Innovation Fund) is a non-traded vehicle giving retail access to late stage private companies including SpaceX. Less liquid than the others. $AGIX (KraneShares AI & Technology ETF) has smaller SpaceX exposure within an AI focused portfolio. SpaceX here is a supporting position, not the main thesis. One thing most people are missing about all of these. When SpaceX lists on June 12 under $SPCX on Nasdaq, the lockup period kicks in for at least six months. These funds don’t immediately convert to public shares. The IPO hype is already priced into them to some degree. SpaceX is targeting $135 per share, raising $75 billion at a $1.75 trillion valuation. Largest IPO in history. Price set June 11, first trade June 12. For pure space economy exposure with SpaceX embedded, $NASA. For maximum SpaceX concentration, $XOVR. For pre IPO tech broadly, $DXYZ. For a diversified growth fund with direct SpaceX shares, $RONB. For AI infrastructure with SpaceX on the side, $AGIX. Same story, very different bets. Know which one you’re actually making. 😉

@jinseongeo83473 👏💯

Fair point on the terminology. The ~$2B+ peak sales target has been consistent. What caught my attention wasn’t the blockbuster label itself but the Black Box Warning context. Veozah capped dosing at 45mg due to hepatotoxicity. ABCL635 showing zero liver toxicity up to 900mg means they have dosing headroom Astellas never had, and that’s where the real upside lives.

$ABCL CFO Andrew Booth at Jefferies yesterday calling ABCL635 a potential blockbuster drug during the NK3R Q&A. CFOs at major healthcare conferences don’t use that word by accident. Think about the context. Veozah launched with a Black Box Warning for liver toxicity and still pulled $234M in 9 months in a market that’s still building. Bayer’s Lynkuet is projecting ~$1B+ in annual sales. Both are small molecules with real limitations. #ABCL635 came back from Phase 1 with zero liver toxicity across all doses from 30mg to 900mg, a half life of 24 days supporting once monthly dosing, and clean target engagement. The dosing headroom Astellas never had is sitting right there. You don’t say blockbuster in a room full of institutional investors unless you mean it. They know what Veozah did with a Black Box Warning. They know what Lynkuet is projecting. And they’re saying ABCL635 is positioned to compete in that same $6B market with a cleaner profile and more room to push efficacy. Goldman at 4.3M shares. Baker Bros at 10.8%. Insider purchase after the data. Stifel raised to $8. Cantor initiated Overweight. JonesResearch at $11. And now the CFO calling it a blockbuster at Jefferies. Q3 topline data is still the moment. But the people who know this drug best keep ending up at😉 x.com/blorrior/statu…

@jinseongeo83473 👍

@BitcoinAgent_C Yap👍

Everyone’s chasing semiconductors, space, and AI right now, and honestly same, I’ve been deep in all of it. But there’s one company I keep coming back to quietly, one that’s building something in a completely different direction. That’s $DMRC Digimarc, and let me explain why it’s been on my radar. They do digital watermarking. Embedding invisible identification into content so you can prove what it is, where it came from, and whether it’s been tampered with. They’ve been doing this for nearly 30 years, and one of their longest running deployments is with a consortium of the world’s central banks to deter currency counterfeiting. Not a new idea for them at all. And honestly the reason this feels more urgent now is pretty obvious when you think about it. AI generated content is everywhere, deepfakes, synthetic images, AI written text, and the question of is this real is getting harder to answer every single day. Digital watermarking is one of the most viable solutions to that problem at scale, and $DMRC has been quietly building the infrastructure for exactly this for decades without much fanfare. The 2026 piece is worth paying attention to though. The EU AI Act comes into full force in May 2026, and it mandates watermarking and labeling of AI generated content across the board. Non compliance means fines up to 15 million EUR or 3% of global annual turnover, whichever is higher. This applies to any AI company operating in Europe, which is basically everyone. What kind of got me was this part. $DMRC developed the industry’s first digital watermarking solution compliant with C2PA 2.1, the standard the industry is converging around, and they co-chair the watermarking task force for that standard. So they’re not just selling into this space, they’re literally at the table where the rules are being written. That’s a different kind of positioning. The honest risk is the financials are still rough. Small cap, still burning cash, stock has been quiet for a while. The story is ahead of the numbers right now. But regulation moving in this direction with $DMRC sitting at the center of the standard, that’s not nothing. Staying on my watchlist for sure.

$MXL up 10% today and the reason is worth understanding properly. Most people have been watching MaxLinear as an optical interconnect story. Keystone PAM4 DSP inside 400G and 800G transceivers. Rushmore targeting 1.6T. That part of the story has been playing out exactly as expected. But today’s news is about something different. MaxLinear and Los Alamos National Laboratory just announced a collaboration on hardware accelerated OpenZFS storage for large scale HPC environments. The numbers from the joint development are pretty striking. 39x speedup for writes. 7x for reads. Against NVMe flash-based infrastructure. Los Alamos isn’t a typical customer to validate against. This is a federally funded national security lab running nuclear weapons simulation, climate modeling, and some of the most demanding supercomputing workloads on the planet. If Panther performs at LANL scale, it performs anywhere. The CEO said it plainly on the Q1 call. 60% of data center spend is in memory. Slow memory access quietly kills inference performance at scale. That’s the problem Panther is designed to solve, and today Los Alamos just publicly confirmed it works. Panther revenue is expected to at least double in 2026 versus 2025. The optical interconnect story was already the first growth leg. Storage acceleration is the second one, and it just got a national security lab’s seal of approval. Both markets are accelerating at the same time, and both are running on $MXL silicon.

Alpha @AlAlphaResearch

4 weeks ago

$MXL keeps adding to the story. Trinity platform just dropped today. URX850 SoC delivering carrier-grade bidirectional wireless backhaul at up to 10Gbps. What used to require multiple separate components, switching, QoS, wireless link aggregation, encryption, and timing

1 0 15 5K 4

. $OPTT is actively pursuing NATO market contracts, and the market is starting to notice that this isn’t just a small marine company anymore. DHS buoys running, autonomous docking demo done, pipeline at $163.9M, and now Europe. And then there’s this from Anduril. US Army just awarded them the Battle Management contract for Western Pacific missile defense, with Lattice integrating distributed sensor data into a single networking layer. From sensor to shooter. Worth noting that $OPTT is an official #Anduril partner. Their PowerBuoys are already feeding real-time data into Lattice off San Diego. Every time Anduril’s Lattice wins a new contract, the sensor network it depends on gets more valuable. OPTT is already a node in that network. The pieces keep connecting. There are risks involved, of course, so please be sure to look into it thoroughly.

Good catch, and fair question. The Q1 earnings call language says “transfer of the PDK to a high-volume semiconductor foundry is underway, with the majority of the integration expected in H2 2026.” They didn’t name the foundry directly. TSMC is the most logical candidate given the scale implied, but I should be clear that it hasn’t been officially confirmed. My post used TSMC as the likely read, not a confirmed fact. Worth keeping that distinction in mind.

A lot has changed since this post $LWLG. And a lot hasn’t. When I wrote this in April, GlobalFoundries and Tower were the foundry story. $TSMC was not yet in the picture. One Fortune Global 500 customer was at Stage 3. Four Fortune Global 500 companies are now at Stage 3. One became four. CEO Yves has said publicly that roughly 80% of Stage 3s eventually advance to Stage 4, which is where volume production begins. And right now, $LWLG is actively negotiating High Volume terms with at least one of those Fortune 500 customers, with H2 2027 as the production timeline target. The foundry story also expanded. GF and Tower were already in. TSMC PDK integration is now on deck. GF, Tower, and TSMC combined represent the vast majority of global silicon photonics production capacity. Getting Perkinamine into all three means any photonics designer at any of those fabs can now design around it without switching foundries. Cash hit $100M by May 11, up from $75.1M on March 31. That $25M increase during the quarter lines up with wafer run timing. Full silicon photonics wafer runs take 12 to 16 weeks. If runs launched in January are tracking for June delivery, the tape-out data is coming soon. The honest risks haven’t changed either. Revenue is still essentially zero, $29,000 in Q1. The stock has pulled back significantly from the $18.71 52-week high to the $11 range, which tells you this is a highly volatile pre commercial name. Stage 3 doesn’t guarantee Stage 4. The 20% of Stage 3s that don’t advance are a real outcome to consider. And the tape-out data, when it comes, will be the next major read on whether the technology performs in real foundry conditions at the specs customers actually need. The original thesis was exactly this. Not the headlines. Whether the tech ends up inside real systems. Four Fortune 500 customers at Stage 3, TSMC coming online, and High Volume negotiations underway is as close to that confirmation as you get before revenue shows up. Still watching. 😉

Alpha @AlAlphaResearch

2 months ago

I started buying $LWLG about a year ago, and it’s already up around 10x. The risk is still there though. That hasn’t changed. It’s still early, not proven at scale, and revenue hasn’t caught up yet. But what has changed is the progress. For a long time it felt like one of those

3 4 35 8K 19

That’s the part I find most underappreciated about $ABCL right now. ABCL688 and ABCL386 both moving toward IND and potentially starting clinical trials around the same time creates a scenario where you could have three programs generating data within a relatively tight window. Q3 for ABCL635, then two more shots at Phase 2 before the end of 2027. That’s a lot of catalysts for a company still trading where it is.

$ABCL has been quietly recovering and the more I sit with this company, the more I think the market is still underestimating what’s actually here. Let me be honest about why I feel this way, because it’s not just the Phase 1 data or the Q3 catalyst, though both matter enormously. It’s the management. Carl Hansen founded this company, still runs it, and owns 20.9% of the outstanding shares. That’s a founder with 20.9% of his own company on the line. When he said on the May 11 earnings call that the Phase 1 data showing robust NK3R target engagement at well-tolerated doses with a pharmacokinetic profile supporting once monthly dosing makes him confident heading into Phase 2, that’s not investor relations language. That’s a scientist who spent years building a platform talking about his own molecule. The financial discipline also reflects that. Q1 revenue of $8.3M, almost double year over year and well ahead of estimates. Loss per share of $0.14 beat the $0.17 consensus. Net loss narrowed. R&D investment increased. Cash and liquidity at $655M with current ratio of 10.2 and minimal debt. For a clinical stage biotech, this is a company being run carefully and thoughtfully, not burning recklessly toward a single bet. And the institutional read keeps getting stronger. Goldman accumulated 4.3M shares in a single quarter. Baker Bros increased from 9.1% to 10.8% the day before the Phase 1 readout. An insider made a fresh purchase on May 18, after the data was already out. Cantor Fitzgerald initiated Overweight. Evan Seigerman reiterated Buy. Analyst consensus around $8-9 against a stock that’s been recovering from well below that. A drug discovery engine with 203 clinical programs and 14 molecules in clinical stage, and ABCL635 is just the most advanced one right now. AI driven discovery that helped develop bamlanivimab in under 90 days during COVID. The platform generates value whether or not any single program succeeds. Phase 2 topline data Q3 2026. $6 billion addressable market with no clean non hormonal solution. A management team with real skin in the game. And a stock that’s been quietly proving the accumulation thesis right. LONG🚀😉#ABCL

Alpha @AlAlphaResearch

3 weeks ago

$ABCL Called the accumulation phase. The stock is coming back. When I posted about treating the post-Phase 1 sell off as an opportunity, the thesis was simple. The data wasn’t bad. The market just wanted efficacy numbers that Phase 1 isn’t designed to deliver. Everything that

5 6 42 10K 5

@jinseongeo83473 @steven_trang4 👍

@Tassel_Man ☺️

@jinseongeo83473 👍😉Let’s goooooo